Arrowhead Pharms
Price
Price
Frequently asked questions
What is Arrowhead Pharms's market capitalization?
What is the Earnings Per Share (EPS) for Arrowhead Pharms?
What are the analyst ratings and target price for Arrowhead Pharms's stock?
What is Arrowhead Pharms's revenue over the trailing twelve months?
What is the EBITDA for Arrowhead Pharms?
What is the free cash flow of Arrowhead Pharms?
What is the 5-year beta of Arrowhead Pharms's stock?
How many employees does Arrowhead Pharms have, and what sector and industry does it belong to?
What is the free float of Arrowhead Pharms's shares?
Financials
Market Cap
$2.30B5Y beta
0.81EPS (TTM)
-$4.651Free Float
118.76MRevenue (TTM)
$19.65MEBITDA (TTM)
-$529.76MFree Cashflow (TTM)
-$531.98MPricing
Analyst Ratings
The price target is $52.43 and the stock is covered by 15 analysts.
Buy
9
Hold
6
Sell
0
Information
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.
525
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker